For the past 20 years, Vanderbilt Health researchers have been studying ifetroban for its potential to treat conditions ranging from fibrotic lung disease to heart failure in patients with Duchenne muscular dystrophy.

Opportunity is measured by the Child Opportunity Index 3.0, a publicly available, multidimensional metric that captures neighborhood conditions that influence children’s health, like education, housing, access to healthy food, environment and societal factors.

In a review of the electronic health records of more than 223,000 veterans treated at Veterans Health Administration facilities, the researchers found that even modest decreases in the normal ABI correlated with a higher risk of major adverse limb events (MALE) requiring intervention, including amputation and revascularization (treatment to restore blood flow).

As aspiration cases at Monroe Carell Jr. Children’s Hospital at Vanderbilt grew, a team of physicians sought to ensure that the most appropriate imaging tools were being used in the evaluation and diagnostic process for suspected aspirations.

Vanderbilt-Ingram Cancer Center is “pushing the envelope” with new technologies like histotripsy and new programs like robotic liver surgery and robotic pancreas surgery, serving patients not only from Tennessee, but also parts of Kentucky, Alabama and Georgia.  

The study is still recruiting participants. It will conclude in 2026 and provide insight for further investigations into the role GLP-1 agonists may offer in treating respiratory illnesses and overall immune responses.

The Vanderbilt Center for Antibody Therapeutics has received large-scale government grants and contracts to fund the discovery of human antiviral antibodies. The problem is the next step — finding corporate partners to develop the antibodies through human testing.